drugset / Trial / NCT04583501

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

NCT04583501

Phase 0 Completed 21 enrolled Johns Hopkins University Genentech, Inc. · collab
NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to examine the mechanism of action of omalizumab in ex vivo tissue culture of whole human nasal polyps from patients with chronic rhino sinusitis with nasal polyposis (CRSwNP), such that specific molecular markers of inflammation can be identified.

Timeline

Start
2020-12-15
Primary completion
2024-07-12
Completion
2024-07-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody 0.016 unknown